Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Value-Based Cancer Care

- PMLiVE

Indegene announces acquisition of Trilogy Writing & Consulting

The deal is aimed at increasing Indegene’s clinical and regulatory writing expertise for global market authorisation applications

- PMLiVE

PMLiVE’s T40 – open for submissions!

Healthcare agencies can submit their entries free of charge with a deadline of 30 April

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

Teva UK and Closed Loop Medicine partner to advance development of personalised medicines

The collaboration will utilise Closed Loop Medicine’s software as a medical device technology platform

- PMLiVE

dna Communications appoints Niamh Mangan as executive vice president and managing director

Mangan joins from 90TEN, where she most recently served as managing director

- PMLiVE

Remembering Paul Stuart-Kregor

Those who worked alongside Paul reflect on his dedication to the healthcare industry and his fellow pharma marketers

- PMLiVE

The anthropologists’ advantage

To impress at the strategic review, you first need to understand its hidden meaning

- PMLiVE

Do omnichannel approaches have a role in market access and payer discussions?

By Frank Fisher and Claire Woon

AMICULUM

- PMLiVE

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

Research Partnership

- PMLiVE

Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

- PMLiVE

AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

- PMLiVE

Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP

Immune thrombocytopenia is estimated to affect up to 100 people per million

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links